Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Diagnostic and Prognostic Value of Thrombin-Antithrombin Complex（TAT）, α2-plasmin Inhibitor-plasmin Complex（PIC）, Tissue Plasminogen Activator-inhibitor Complex（tPAI·C） and Thrombomodulin（TM） in Sepsis-induced Coagulopathy

NCT06379126 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06379126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06379126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Diagnostic and Prognostic Value of Thrombin-Antithrombin Complex（TAT）, α2-plasmin Inhibitor-plasmin Complex（PIC）, Tissue Plasminogen Activator-inhibitor Complex（tPAI·C） and Thrombomodulin（TM） in Sepsis-induced Coagulopathy
Lead sponsor
The First Hospital of Jilin University
Phase
Observational
Overall status
Unknown status
Start date
April 20, 2024
Completion date
April 20, 2026
Enrollment
210 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis-induced coagulopathy